Secondary osteoarthritis of the ankle in a patient aged 82. Credit: Jmarchn.

Galapagos has dosed the first patient in Phase ll ROCCELLA trial investigating the efficacy and safety of GLPG1972/S201086 for the treatment of patients with knee osteoarthritis (OA).

The multiregional, randomised, double-blind, placebo-controlled, dose-ranging trial intends to examine three different once-daily doses of GLPG1972/S201086.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial is expected to enrol around 850 patients in various countries across Europe, Asia, North America and South America.

Its primary endpoint is to demonstrate the efficacy of at least one dose of GLPG1972/S201086 versus placebo in minimising cartilage loss after 52 weeks of treatment. The cartilage loss will be measured by magnetic resonance imaging (MRI).

The trial’s secondary endpoints comprise safety and tolerability. Its additional goals are structural progression, improvement in pain, function, stiffness, and patient global assessment.

“GLPG1972/S201086 is a disease-modifying osteoarthritis drug (DMOAD) candidate that, in two animal models, has been shown to efficiently target a cartilage degrading enzyme called ADAMTS-5.”

ROCCELLA will be conducted as part of a collaboration between Galapagos and Servier.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Galapagos will look after the trial in the US, where 300 patients are expected to be enrolled, while Servier will conduct the trial in all other countries.

Galapagos in a statement said: “GLPG1972/S201086 is a disease-modifying osteoarthritis drug (DMOAD) candidate that, in two animal models, has been shown to efficiently target a cartilage degrading enzyme called ADAMTS-5.

“A Phase l trial in healthy volunteers met all of its safety and pharmacokinetic targets and also demonstrated that GLPG1972/S201086 reduced the blood level of the ARGS neoepitope by approximately 50% within two weeks.”

There are currently no treatments available for countering OA, which is a highly prevalent and disabling pathology.